BioMarin Pharmaceutical Inc.: Sales Up, Losses Down, Waiting on Pipeline – Motley Fool


Motley Fool
BioMarin Pharmaceutical Inc.: Sales Up, Losses Down, Waiting on Pipeline
Motley Fool
The Motley Fool recommends BioMarin Pharmaceutical. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.
BioMarin Pharmaceutical Inc. (BMRN) Given Neutral Rating at WedbushThe Cerbat Gem
BioMarin Pharmaceutical Inc. (BMRN) Releases FY16 Earnings GuidanceBBNS
BioMarin Pharmaceutical Inc. (BMRN) Forecasted to Post FY2019 Earnings of $0.36 Per ShareCommunity Financial News
TheFounders Daily -Evergreen Investor
all 41 news articles >>

Source: pharmaceutical – Google News

Sharing information is key – Pharmaceutical Business News UK. Social Commerce and Social Media Management playing a big part. Suaju Ltd